Biodextris, Inc.
Biodextris is a leading Canadian CDMO specializing in biologics and vaccine development, with over 20 years of experience in high-value complex biologic products. Based in Laval, Quebec, it develops, manufactures, and tests a wide range of biologic products for vaccine, pharmaceutical, and other applications, supporting clients from pre-clinical to commercialization. The company emphasizes innovation, quality, and customer-centric approaches, and has recently expanded its facilities with significant investments supported by government programs. Biodextris aims to accelerate its growth and global presence through strategic partnerships and a project-based collaboration model.
Industries
Nr. of Employees
small (1-50)
Biodextris, Inc.
245 Boulevard Armand-Frappier, Laval, QC H7V 4A7, Canada
Products
Clinical and preclinical biologic materials
Development and manufacture of proteins, antibodies, enzymes and peptides suitable for preclinical and clinical studies, produced under cGMP or GLP conditions as required.
Nucleic-acid clinical batch production (plasmid and mRNA)
Process development and clinical-batch manufacturing support for plasmid DNA and mRNA-based therapeutics and vaccines, including downstream production and analytical characterization.
Clinical and preclinical biologic materials
Development and manufacture of proteins, antibodies, enzymes and peptides suitable for preclinical and clinical studies, produced under cGMP or GLP conditions as required.
Nucleic-acid clinical batch production (plasmid and mRNA)
Process development and clinical-batch manufacturing support for plasmid DNA and mRNA-based therapeutics and vaccines, including downstream production and analytical characterization.
Services
Method development, validation, transfer, GMP QC testing and stability studies for biologics and small molecules using physicochemical, biophysical and immunological techniques.
Upstream and downstream process development, purification, formulation, cell-banking and process transfer to produce manufacturing-ready processes and support technical transfer to GMP operations.
cGMP biomanufacturing of proteins, antibodies and nucleic-acid therapeutics for preclinical and clinical use, including segregated GMP suites, pilot-scale bioreactors, cell banking and aseptic fill–finish.
Provision and operation of custom cGMP facilities with segregated manufacturing suites, controlled warehousing and analytical laboratories to support projects from preclinical development through clinical manufacturing.
Facility-based downstream manufacturing and clinical supply services for vaccines produced using plant-expression systems, including preparation of clinical material for early-phase trials.
Method development, validation, transfer, GMP QC testing and stability studies for biologics and small molecules using physicochemical, biophysical and immunological techniques.
Upstream and downstream process development, purification, formulation, cell-banking and process transfer to produce manufacturing-ready processes and support technical transfer to GMP operations.
cGMP biomanufacturing of proteins, antibodies and nucleic-acid therapeutics for preclinical and clinical use, including segregated GMP suites, pilot-scale bioreactors, cell banking and aseptic fill–finish.
Provision and operation of custom cGMP facilities with segregated manufacturing suites, controlled warehousing and analytical laboratories to support projects from preclinical development through clinical manufacturing.
Facility-based downstream manufacturing and clinical supply services for vaccines produced using plant-expression systems, including preparation of clinical material for early-phase trials.
Expertise Areas
- Analytical method development and bioanalysis
- cGMP biomanufacturing for clinical materials
- Upstream and downstream process development and scale-up
- Cell line development and cell banking
Key Technologies
- High-performance liquid chromatography (HPLC/UPLC)
- High-resolution mass spectrometry
- Size-exclusion chromatography with multi-angle light scattering (SEC-MALS)
- Capillary isoelectric focusing (cIEF)
News & Updates
Biodextris has opened new laboratories in Laval, supported by nearly $25 million in investments, to support its development, clinical manufacturing, and packaging of vaccines and biologics. The expansion aims to quadruple production capacity and increase workforce, with new divisions for biotherapeutics using mRNA and plasmid technologies.
Dr. Mahdavi, a biopharma veteran with over 25 years of experience, has been appointed to spearhead Biodextris' global expansion, leveraging his expertise in commercial innovation and international market development.
Biodextris emphasizes flexible, segmental project collaborations with biopharma sponsors, aligning costs with funding phases and mitigating risks, to optimize resources and foster innovation.
Biodextris offers advanced analytical services including method development, validation, transfer, and GMP-compliant testing for biologics and small molecules.
Biodextris and Aramis Biotechnologies have signed a strategic partnership to collaborate on the efficient downstream manufacturing of clinical materials for Aramis' influenza vaccine candidate, leveraging Biodextris' expertise and facilities.
Biodextris partnered with Aramis to ensure efficient downstream manufacturing of clinical materials for influenza vaccine candidates, leveraging state-of-the-art facilities and expertise.
Biodextris has opened new laboratories in Laval, supported by nearly $25 million in investments, to support its development, clinical manufacturing, and packaging of vaccines and biologics. The expansion aims to quadruple production capacity and increase workforce, with new divisions for biotherapeutics using mRNA and plasmid technologies.
Dr. Mahdavi, a biopharma veteran with over 25 years of experience, has been appointed to spearhead Biodextris' global expansion, leveraging his expertise in commercial innovation and international market development.
Biodextris emphasizes flexible, segmental project collaborations with biopharma sponsors, aligning costs with funding phases and mitigating risks, to optimize resources and foster innovation.
Biodextris offers advanced analytical services including method development, validation, transfer, and GMP-compliant testing for biologics and small molecules.
Biodextris and Aramis Biotechnologies have signed a strategic partnership to collaborate on the efficient downstream manufacturing of clinical materials for Aramis' influenza vaccine candidate, leveraging Biodextris' expertise and facilities.
Biodextris partnered with Aramis to ensure efficient downstream manufacturing of clinical materials for influenza vaccine candidates, leveraging state-of-the-art facilities and expertise.